home korean

Service models

Drug testing platform using iPSC

The iPSC-based system replicates patients’ immune systems in a test tube for customized efficacy evaluation. It provides platforms for patient-specific osteoblast, cartilage cells and skin tissues using induced pluripotent stem cells (iPSC) derived from patient’s blood cells. The drug efficacy is tested with in-vitro assay.

보유모델 정보
Model Evaluation interval Evaluation items
Cartilage cells
1~10 days after differentiation (takes 21~30 days)
  • RT-PCR, IFA of iPSC
  • Osteoimage bone mineralization assay (osteoblast)
  • Immunohistochemistry image (cartilage cells)
  • Alcian blue stain and analysis (cartilage cells)
Systemic sclerosis (3D skin organoid) 3 weeks after differentiation (takes 3 weeks)
  • 3D skin organoid
  • Keratinocyte, fibroblast differentiation, marker check
  • Skin morphology, thickness, collagen pattern
  • Extracellular matrix
  • Cell viability, proliferation

Service analysis

Patient-specific iPSC

  • Generation of iPSC from patient’s PBMC
  • iPSC quality control: RT-PCR, IFA
  • iPSC banking

Differentiation of iPSC-derived osteoblast and cartilage cells

  • Use of iPSC for differentiation into osteoblast/cartilage cells
  • Genetic marker analysis of osteoblast/cartilage cells
  • Drug treatment to platform of osteoblast/cartilage cells
  • Osteoblast: Osteoimage bone mineralization assay
  • Cartilage cells: Immunohistochemistry image analysis
  • Alzarin red stain and analysis

Systemic sclerosis (3D skin organoid)

  • Use of patient’s iPSC for differentiation of fibroblast and keratinocyte/ marker analysis/ production of 3D skin organoid
  • Drug treatment to 3D skin organoid
  • Analysis of skin morphology, thickness, collagen pattern
  • ECM analysis (IHC, IFA, western blot, qRT-PCR)
  • Whole 3D skin graft (SCID mice)*
* Premium Service